Literature DB >> 1679333

Stimulation of B and T cells by in vivo high dose immunoglobulin administration in normal mice.

A Sundblad1, F Huetz, D Portnoï, A Coutinho.   

Abstract

Adult BALB/c mice were injected intravenously with a preparation of pooled normal murine IgG (400 mg/kg/day, on five consecutive days) and studied 8, 15, and 60 days later. High dose IgG administration increased the total numbers of splenic activated B and CD4+ (but not CD8+) T cells, as well as the numbers of splenic Ig-secreting cells, particularly in the IgG isotypes. Reactivities to some autoantigens, but not to bacterial or other heteroantigens, were selectively amplified amongst IgM-secreting cells. IgG administration did not alter the specific primary immune response to heterologous erythrocytes or bacterial dextran. No cellular alterations were detected in the lymph nodes or peritoneal cavity of treated animals. Most of these effects subsided with time, but some autoantibody reactivities remained elevated 60 days later. The present results suggest that the therapeutic effects of high dose IgG administration which have been reported in human diseases might be associated with the immunostimulatory activities of such treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679333     DOI: 10.1016/0896-8411(91)90028-b

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  7 in total

Review 1.  Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute.

Authors:  Miglena G Prabagar; Hyeong-jwa Choi; Jin-Yeon Park; Sohee Loh; Young-Sun Kang
Journal:  Clin Exp Med       Date:  2013-09-01       Impact factor: 3.984

Review 2.  Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases.

Authors:  S V Kaveri; G Dietrich; V Hurez; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1991-11       Impact factor: 4.330

Review 3.  Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.

Authors:  Luca Cantarini; Donato Rigante; Antonio Vitale; Salvatore Napodano; Lazaros I Sakkas; Dimitrios P Bogdanos; Yehuda Shoenfeld
Journal:  Immunol Res       Date:  2015-03       Impact factor: 2.829

4.  Suppression of allo-human leucocyte antigen (HLA) antibodies secreted by B memory cells in vitro: intravenous immunoglobulin (IVIg) versus a monoclonal anti-HLA-E IgG that mimics HLA-I reactivities of IVIg.

Authors:  D Zhu; M H Ravindranath; P I Terasaki; T Miyazaki; T Pham; V Jucaud
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

5.  Anti-idiotypic activity against anti-myeloperoxidase antibodies in pooled human immunoglobulin.

Authors:  A A Pall; M Varagunam; D Adu; N Smith; N T Richards; C M Taylor; J Michael
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

Review 6.  HLA Class Ia and Ib Polyreactive Anti-HLA-E IgG2a Monoclonal Antibodies (TFL-006 and TFL-007) Suppress Anti-HLA IgG Production by CD19+ B Cells and Proliferation of CD4+ T Cells While Upregulating Tregs.

Authors:  Mepur H Ravindranath
Journal:  J Immunol Res       Date:  2017-05-28       Impact factor: 4.818

7.  Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?

Authors:  Laetitia Sordé; Sebastian Spindeldreher; Ed Palmer; Anette Karle
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.